Results 141 to 150 of about 15,983 (179)

Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair-Deficient Uterine Leiomyosarcoma. [PDF]

Clin Cancer Res
Lee HHY, Chow KL, Wong HS, Chong TY, Wong AST, Cheng GHW, Ko JMK, Siu HC, Yeung MCF, Huen MSY, Tse KY, Bray MR, Mak TW, Leung SY, Ip PPC.   +14 more
europepmc   +1 more source

Correction for Park et al., Specific inhibition of an anticancer target, polo-like kinase 1, by allosterically dismantling its mechanism of substrate recognition. [PDF]

Proc Natl Acad Sci U S A
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Polo-Like Kinases Inhibitors

Current Medicinal Chemistry, 2012
Polo-like kinases (PLKs) are a family of serine/threonine kinases that play crucial roles in multiple stages of mitosis. PLK1 is the most studied member of the family. It is overexpressed in a wide spectrum of cancer types and is a promising target in oncology. Most of PLK1 inhibitors are ATP-competitive.
GARUTI, LAURA, ROBERTI, MARINELLA, BOTTEGONI, GIOVANNI   +2 more
openaire   +3 more sources

The family of polo-like kinases

1996
Here we discuss members of a new family of serine/threonine protein kinases with a likely role in cell cycle control. These kinases are referred to as polo-like kinases, after the prototypic founding member of the family, the polo gene product of Drosophila melanogaster. The polo kinase was originally identified in mutants that display abnormal mitotic
Lynne D. Berry, Roy M. Golsteyn, Heidi A. Lane, Kirsten E. Mundt, Lionel Arnaud, Erich A. Nigg   +5 more
openaire   +2 more sources

Polo-like kinases and acute leukemia

Oncogene, 2018
Acute leukemia is a common malignancy among children and adults worldwide and many patients suffer from chronic health issues using current therapeutic approaches. Therefore, there is a great need for the development of novel and more specific therapies with fewer side effects.
Oksana, Goroshchuk, Iryna, Kolosenko, Linda, Vidarsdottir, Alireza, Azimi, Caroline, Palm-Apergi   +4 more
openaire   +2 more sources

Progress in the Discovery of Polo-like Kinase Inhibitors

Current Topics in Medicinal Chemistry, 2005
Polo-like kinases (PLKs) are key enzymes that control mitotic entry of proliferating cells and regulate many aspects of mitosis necessary for successful cytokinesis. Of the four known human PLKs, PLK1 is the best characterized and is overexpressed in many tumour types with aberrant elevation frequently constituting a prognostic indicator of poor ...
Campbell, McInnes, Mokdad, Mezna, Peter M, Fischer   +2 more
openaire   +2 more sources

Polo-like kinases and the orchestration of cell division

Nature Reviews Molecular Cell Biology, 2004
Polo-like kinases (Plks) are increasingly recognized as key regulators of mitosis, meiosis and cytokinesis. In agreement with a broad range of proposed functions during cell division, Plks are subject to complex temporal and spatial control. Recent findings are uncovering the mechanisms of Plk regulation, notably their targeting to different cellular ...
Barr, Francis A., Silljé, Herman H. W., Nigg, Erich A.   +2 more
openaire   +3 more sources

Polo-like kinase inhibitor BI2536 induces eryptosis

Wiener Medizinische Wochenschrift, 2022
BI2536 is potent inhibitor of polo-like kinases PLK1, 2, and 3. The inhibition of PLKs in nucleated cells induces apoptosis by perturbing the cell cycle with consequent engagement of mitotic catastrophe. BI2536 is being tested as chemotherapy in various phase I/II/III clinical trials.
Mohamed, Jemaà, Raja, Mokdad Gargouri, Florian, Lang   +2 more
openaire   +2 more sources

Polo-like kinase inhibitors in hematologic malignancies

Critical Reviews in Oncology/Hematology, 2016
Polo-like kinases (Plk) are key regulators of the cell cycle and multiple aspects of mitosis. Two agents that inhibit the Plk signaling pathway have shown promising activity in patients with hematologic malignancies and are currently in phase III trials.
Chetasi Talati, Elizabeth A. Griffiths, Meir Wetzler, Eunice S. Wang   +3 more
openaire   +2 more sources

Discovery of thiophene inhibitors of polo-like kinase

Bioorganic & Medicinal Chemistry Letters, 2009
The discovery and development of a series of thiophenes as potent and selective inhibitors of PLK is described. Identification and characterization of 2, a useful in vitro PLK inhibitor tool compound, is also presented.
Kyle A, Emmitte, C Webb, Andrews, Jennifer G, Badiang, Ronda G, Davis-Ward, Hamilton D, Dickson, David H, Drewry, Holly K, Emerson, Andrea H, Epperly, Daniel F, Hassler, Victoria B, Knick, Kevin W, Kuntz, Timothy J, Lansing, James A, Linn, Robert A, Mook, Kristen E, Nailor, James M, Salovich, Glenn M, Spehar, Mui, Cheung   +17 more
openaire   +2 more sources